CLIENT RESULT
Pharma

An ex-U.S. NGS playbook for a precision oncology pipeline.

Andrew Aijian, PhD

Partner
View Profile
capabilities
Product Strategy / Portfolio Planning
Project Details
capability
Product Strategy / Portfolio Planning

Objective

A leading global pharma company with a maturing NGS-dependent oncology portfolio needed a strategic framework to plan market development ahead of launch across six ex-U.S. regions. Andrew's team produced the architecture and the launch-relative roadmap the cross-functional team aligned on.
Key Metrics
6
Ex-U.S. Regions Assessed
5
Strategic Opportunity Spaces
16
Internal Stakeholders Consulted

Our Approach

A senior life sciences team with deep fluency in NGS market structures across the regions in scope led the engagement. The framework converged through three lines of activity.

The first established a shared baseline. DeciBio built a structured landscape assessment framework spanning testing infrastructure, access and reimbursement, policy and guidelines, technology adoption, and stakeholder education across the six ex-U.S. regions. The team layered its own market knowledge against the client’s regional intelligence, identified the gaps, and aligned the working group on a consensus view of where each market actually sat, not where it was assumed to sit.

The second translated that baseline into a strategic architecture. Through structured discussions with sixteen stakeholders across the client’s precision medicine, medical affairs, biomarker strategy, research labs, and market access functions, the team surfaced the considerations that had to shape the framework: the asset-class typology, the role of NGS in each market, and the kind of investment posture the organization could sustain. The architecture that emerged structured the strategy as a vision supported by five opportunity spaces (infrastructure, access, policy, technology, and education), each carrying its own goals and a calibrated set of actions.

The third converged the work into a launch-relative roadmap. A full-day in-person workshop with the cross-functional NGS working group pressure-tested the architecture against asset realities, sequenced the actions on a two-and-a-half-year pre-launch timeline, and assigned each action to the functional teams responsible for executing it.

Outcome

The team came away with a strategic framework calibrated to the realities of each ex-U.S. market and the assets that would have to launch into them. The architecture (vision, opportunity spaces, goals, actions) gave the global precision medicine team a structure for prioritizing where to invest, and gave each regional team a calibrated action set tied to launch timing. Where NGS market development had often been organized around individual assets and individual markets, the framework gave the organization a way to coordinate across both at once.

As new assets enter development and as regional NGS landscapes evolve, the same architecture can continue to structure where investment should sit, what readiness looks like in each market, and when work needs to start. The cross-functional alignment that came out of the workshop carried forward into how the global precision medicine team and its regional counterparts can operate against the next wave of NGS-dependent launches.

Project Details
Geographic Scope
Ex-U.S., spanning Northern Europe, Southern Europe, Canada, APAC, Japan, and LATAM
Precision Medicine is evolving at a rapid pace

Discover how we can help

Get in Touch